Breast Implant Safety: What the FDA Requires You to Know

Published 2026-08-19 by the BeautyVetted editorial team · Written by the BeautyVetted team, sources linked in the text

If you are researching breast augmentation, there is a set of documents you are legally entitled to see before you agree to anything. Most patients do not know they exist. They are worth reading closely, because they were written specifically so that you could make this decision with real information in front of you.

What changed in 2021

On October 27, 2021, the FDA took several actions to strengthen how breast implant risks are communicated to patients.

The agency restricted the sale and distribution of breast implants, so that they may only go to providers and facilities that give patients risk information in the form the approved labeling specifies. Alongside that, the FDA approved new labeling for every legally marketed breast implant in the United States. That labeling now has to include five things:

A boxed warning, the most serious warning the FDA applies.
A patient decision checklist, which your provider has to review with you.
Updated screening guidance for silicone gel implant rupture.
A device description listing the specific materials in the implant.
A patient device card, given to you after surgery, with the details of your specific implants.

The checklist is not a formality. The FDA requires that you be given the chance to initial and sign it, and that the physician implanting the device signs it too. You are meant to work through it item by item, in conversation, with your questions answered before you initial anything.

You have the right to ask your surgeon for a copy of the patient labeling for the exact implant they plan to use, and the FDA states plainly that your physician is expected to provide it. Ask at the consultation, not on the day of surgery.

Implants are not lifetime devices

This is the single sentence the FDA repeats most often, and it reframes the whole decision.

Breast implants are not lifetime devices. The longer you have them, the more likely it becomes that you will need them removed or replaced. The FDA’s guidance goes further and advises that you should assume you will need additional surgeries, because complications can occur and implants do not last indefinitely.

That reframes breast augmentation from a single event into something ongoing. It also has a financial dimension the FDA calls out directly: even when you have complications, the cost of implant removal or replacement may not be covered by insurance, and some insurers will not cover removal even if they covered the original surgery. Our breast augmentation cost guide covers the first surgery, but the long view is worth budgeting for.

The most common local complications are capsular contracture, reoperation, and implant removal. Others include rupture or deflation, rippling, asymmetry, scarring, pain, and infection at the incision site.

Rupture screening for silicone implants

Silicone implants can rupture at any point, and the longer an implant is in place the greater that possibility becomes.

The complicating detail is that most silicone ruptures produce no symptoms at all. The FDA calls these silent ruptures. A silent rupture usually does not change how the implant looks or feels, and a surgeon often cannot detect one by physical examination alone.

For that reason implants need monitoring for as long as you have them. The FDA states that MRI is the most effective method for detecting silent rupture of silicone gel implants, and since a December 2023 update, ultrasound is an acceptable alternative for screening patients who have no symptoms. These scans may not be covered by your insurance.

Sometimes a rupture does announce itself. Signs can include a decrease in breast size, a change in shape, hard lumps over the implant or chest, uneven appearance, pain or tenderness, tingling, swelling, numbness, or burning. Any of those warrant a prompt call to your surgeon.

Ask your surgeon directly when your first screening scan should happen and how often after that, and ask what it will cost.

BIA-ALCL

Breast implant associated anaplastic large cell lymphoma is a type of non-Hodgkin’s lymphoma, a cancer of the immune system. It is not breast cancer. In most cases it is found in the scar tissue and fluid near the implant, though it can spread through the body.

The FDA describes an individual’s risk of developing BIA-ALCL as low. It also states that the cancer is serious and can lead to death, particularly if it is not treated promptly. In most patients it is treated successfully by removing the implant and the surrounding scar tissue, and some patients also need chemotherapy or radiation.

Two facts are worth carrying into a consultation. The risk is higher with textured surface implants than with smooth surface implants, and the type of fill, silicone or saline, does not appear from current data to be a risk factor. Ask which surface texture your surgeon plans to use, and why.

The main symptoms are persistent swelling, a mass, or pain in the area of the implant. These often appear years after the implant was placed, well after the incision healed. For patients without symptoms, the FDA does not advise removing implants over BIA-ALCL concern. The FDA has also received reports of squamous cell carcinoma and other lymphomas in the capsule around implants.

Systemic symptoms and how to report them

Some patients report fatigue, memory loss, rash, brain fog, and joint pain. Many use the term breast implant illness to describe this cluster.

The FDA’s position is candid: these symptoms and their causes are poorly understood, and researchers are still investigating. In some cases, removing implants without replacing them has been reported to reverse the symptoms. The FDA has not detected an association between silicone gel implants and breast cancer or reproductive problems, while noting that fully understanding these questions would require larger and longer studies than have been done.

If you have implants and experience symptoms, you can report them to the FDA yourself through MedWatch, or by phone at 1-800-FDA-1088. Include the device brand name, the manufacturer, and details of what you experienced. Patient reports are part of how this evidence base gets built.

Bringing it to your consultation

Read the patient labeling and the decision checklist before you sign anything, and treat every item you do not understand as a question rather than a formality. If you want a broader list to work from, our twelve questions to ask at a consultation covers facilities, anesthesia, and revision policy, and the breast augmentation procedure guide explains what the surgery itself involves.